CelLBxHealth plc Share Price
Stocks
CLBX
GB0034330679
Advanced Medical Equipment & Technology
OTC Markets Traded|
Delayed
London S.E.
05:22:20 19/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 0.8300 GBX | +3.75% |
|
-2.35% | -24.55% |
| 14/10 | CelLBxHealth expands services deal with US pharmaceutical firm | AN |
| 14/10 | Cellbxhealth Expands Parsortix Platform Partnership with Pharmaceutical Company in US | MT |
| Market Cap | 90.91L 1.21Cr 1.08Cr 99.92L 1.72Cr 115.1Cr 1.74Cr 12Cr 4.71Cr 60Cr 4.55Cr 4.45Cr 191.48Cr | P/E 2026 * |
-0.34x | P/E 2027 * | -8.89x |
|---|---|---|---|---|---|
| Enterprise Value | 74.91L 99.94L 88.83L 82.34L 1.41Cr 95Cr 1.44Cr 9.9Cr 3.88Cr 49Cr 3.75Cr 3.67Cr 157.78Cr | EV / Sales 2026 * |
0.5x | EV / Sales 2027 * | 0.39x |
| Free-Float |
95.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| CLBX | Delayed | |
Deutsche Boerse AG
| DWV | Delayed |
Last Transcript: CelLBxHealth plc
| 16/25/16 | Angle names Peter Collins as interim CEO | AN |
| 28/25/28 | RBC cuts National Grid; Citigroup cuts South32 | AN |
| 23/25/23 | HSBC raises FirstGroup, Goldman cuts Ithaca | AN |
| 14/23/14 | JPMorgan ups Rio Tinto; Redburn likes Carnival | AN |
| 24/22/24 | Berenberg Initiates Angle With Buy Rating, Sets PT | MT |
| 1 day | +3.75% | ||
| 1 week | -2.35% | ||
| Current month | -2.35% | ||
| 1 month | -17.00% | ||
| 3 months | -33.60% | ||
| 6 months | -14.87% | ||
| Current year | -24.55% |
| 1 week | 0.78 |  | 1 |
| 1 month | 0.7 | | 1.1 |
| Current year | 0.7 | | 2.8 |
| 1 year | 0.7 | | 3.5 |
| 3 years | 0.7 | | 37.4 |
| 5 years | 0.7 | | 163.75 |
| 10 years | 0.7 | | 163.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sinéad Armstrong
DFI | Director of Finance/CFO | - | 01/01/1999 |
| Chief Tech/Sci/R&D Officer | - | 01/01/2025 | |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 05/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Groen
CHM | Chairman | 67 | 22/05/2023 |
Klaas de Boer
BRD | Director/Board Member | 61 | 12/01/2026 |
| Director/Board Member | 61 | 12/01/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 19/12/25 | Buy | Chief Executive Officer | 50,00,000 | 1.5497% | ||
| 19/12/25 | Buy | Chief Financial Officer | 25,00,000 | 0.7749% | ||
| 19/12/25 | Buy | Chairman | 50,00,000 | 1.5497% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.75% | -2.35% | -55.14% | -92.78% | 1.21Cr | |
| -0.93% | +4.86% | +28.03% | +47.67% | 26TCr | |
| -1.06% | +4.20% | +9.56% | +11.84% | 16TCr | |
| -0.27% | +0.65% | -4.36% | +54.87% | 15TCr | |
| +0.57% | +3.88% | -55.27% | -12.46% | 6.43TCr | |
| -1.56% | +3.18% | -15.46% | -11.17% | 5.19TCr | |
| -0.85% | +4.81% | +9.39% | +50.51% | 5.03TCr | |
| -1.70% | +1.63% | +16.02% | +24.23% | 4.99TCr | |
| -1.47% | +1.42% | +21.88% | +59.26% | 4.88TCr | |
| -1.62% | +0.73% | +30.59% | +75.83% | 4.29TCr | |
| Average | -0.45% | +2.22% | -1.48% | +20.78% | 8.75TCr | |
| Weighted average by Cap. | -0.55% | +3.42% | +8.37% | +35.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.51Cr 2.02Cr 1.79Cr 1.66Cr 2.86Cr 191.6Cr 2.9Cr 20Cr 7.84Cr 100Cr 7.58Cr 7.42Cr 318.74Cr | 2.7Cr 3.61Cr 3.21Cr 2.97Cr 5.1Cr 342.27Cr 5.18Cr 36Cr 14Cr 178.61Cr 14Cr 13Cr 569.38Cr |
| Net income | -85.5L -1.14Cr -1.01Cr -93.97L -1.61Cr -108.25Cr -1.64Cr -11Cr -4.43Cr -56Cr -4.28Cr -4.19Cr -180.08Cr | -18.5L -24.68L -21.94L -20.33L -34.91L -23Cr -35.47L -2.44Cr -95.83L -12Cr -92.62L -90.65L -39Cr |
| Net Debt | -16L -21.34L -18.97L -17.59L -30.19L -20Cr -30.68L -2.11Cr -82.88L -11Cr -80.11L -78.4L -34Cr | 14L 18.68L 16.6L 15.39L 26.42L 18Cr 26.84L 1.85Cr 72.52L 9.25Cr 70.09L 68.6L 29Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/26/19 | GBX 0.8300 | +3.75% | 2,13,193 |
| 16/26/16 | GBX 0.8000 | -3.03% | 43,14,280 |
| 15/26/15 | GBX 0.8250 | -2.94% | 24,01,959 |
| 14/26/14 | GBX 0.8500 | -8.11% | 44,12,016 |
| 13/26/13 | GBX 0.9250 | +8.82% | 37,45,113 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- CLBX Stock
Select your edition
All financial news and data tailored to specific country editions
